Phencyclidine-induced changes in rat cortical gene expression identified by microarray analysis: Implications for schizophrenia

Neurobiology of Disease

Volumn 16, Issue 1, 2004, Pages 220-235

  Kaiser, Sergio ^a   Foltz, Lisa A ^a   George, Carolyn A ^a   Kirkwood, Sandra C ^a   Bemis, Kerry G ^a   Lin, Xi ^a   Gelbert, Lawrence M ^a   Nisenbaum, Laura K ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Animal model; Brain cortex; False discovery rate; GeneChip; Psychotomimetic

Indexed keywords

PHENCYCLIDINE; THYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINEAGE; COGNITIVE DEFECT; CONTROLLED STUDY; DEVELOPMENT; DNA MICROARRAY; GENE CONTROL; GENE EXPRESSION; GROWTH; HORMONE ACTION; INFLAMMATION; LIPID METABOLISM; MALE; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIA; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SLEEP; STATISTICAL ANALYSIS; STRESS; THALAMOCORTICAL TRACT; UNINDEXED SEQUENCE; VELOCARDIOFACIAL SYNDROME;

ANIMALS; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA;

EID: 2342614288     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2004.01.011     Document Type: Article

References (150)

1. Adams B., Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J. Neurosci. 18:1998;5545-5554
2. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K., Flach K., Nagamoto H., Bickford P., Leonard S., Freedman R. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr. Bull. 24:1998;189-202
3. Adler C.M., Malhotra A.K., Elman I., Goldberg T., Egan M., Pickar D., Breier A. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J. Psychiatry. 156:1999;1646-1649
4. Akanuma N., Saitoh O., Yoshikawa T., Matsuda H., Ishikura N., Kato M., Adachi N., Onuma T. Interictal schizophrenia-like psychosis in a patient with double cortex syndrome. J. Neuropsychiatry Clin. Neurosci. 14:2002;210-213
5. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney W.E. Jr., Jones E.G. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry. 52:1995;258-266
6. Ananth H., Popescu I., Critchley H.D., Good C.D., Frackowiak R.S., Dolan R.J. Cortical and subcortical gray matter abnormalities in schizophrenia determined through structural magnetic resonance imaging with optimized volumetric voxel-based morphometry. Am. J. Psychiatry. 159:2002;1497-1505
7. Andersen M.B., Fink-Jensen A., Peacock L., Gerlach J., Bymaster F., Lundbaek J.A., Werge T. The muscarinic M(1)/M(4) receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology. 28:2003;1168-1175
8. Andreasen N.C., Flashman L., Flaum M., Arndt S., Swayze V., O'Leary D.S., Ehrhardt J.C., Yuh W.T. Regional brain abnormalities in schizophrenia measured with magnetic resonance imaging. JAMA. 272:1994;1763-1769
9. Angelopoulos E.K., Markianos M., Daskalopoulou E.G., Hatzimanolis J., Tzemos J. Changes in central serotonergic function as a correlate of duration of illness in paranoid schizophrenia. Psychiatry Res. 110:2002;9-17
10. Arispe N., Doh M. Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AbetaP (1-40) and (1-42) peptides. FASEB J. 16:2002;1526-1536
11. Bassett A.S., Chow E.W. 22q11 deletion syndrome: a genetic subtype of schizophrenia. Biol. Psychiatry. 46:1999;882-891
12. Bayer L., Eggermann E., Saint-Mleux B., Machard D., Jones B.E., Muhlethaler M., Serafin M. Selective action of orexin (hypocretin) on nonspecific thalamocortical projection neurons. J. Neurosci. 22:2002;7835-7839
13. Benjamini Y., Drai D., Elmer G., Kafkafi N., Golani I. Controlling the false discovery rate in behavior genetics research. Behav. Brain Res. 125:2001;279-284
14. Benson K.L., Sullivan E.V., Lim K.O., Lauriello J., Zarcone V.P. Jr., Pfefferbaum A. Slow wave sleep and computed tomographic measures of brain morphology in schizophrenia. Psychiatry Res. 60:1996;125-134
15. Berman K.F., Weinberger D.R. The prefrontal cortex in schizophrenia and other neuropsychiatric diseases: in vivo physiological correlates of cognitive deficits. Prog. Brain Res. 85:1990;521-536
16. Bishop J.O., Morton J.G., Rosbash M., Richardson M. Three abundance classes in HeLa cell messenger RNA. Nature. 250:1974;199-204
17. Broide R.S., Robertson R.T., Leslie F.M. Regulation of alpha7 nicotinic acetylcholine receptors in the developing rat somatosensory cortex by thalamocortical afferents. J. Neurosci. 16:1996;2956-2971
18. Bymaster F.P., Felder C., Ahmed S., McKinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr. Drug Target CNS Neurol. Disord. 1:2002;163-181
19. Carter C.S., Perlstein W., Ganguli R., Brar J., Mintun M., Cohen J.D. Functional hypofrontality and working memory dysfunction in schizophrenia. Am. J. Psychiatry. 155:1998;1285-1287
20. Cochran S.M., Fujimura M., Morris B.J., Pratt J.A. Acute and delayed effects of phencyclidine upon mRNA levels of markers of glutamatergic and GABAergic neurotransmitter function in the rat brain. Synapse. 46:2002;206-214
21. Conti L.H., Murry J.D., Ruiz M.A., Printz M.P. Effects of corticotrophin-releasing factor on prepulse inhibition of the acoustic startle response in two rat strains. Psychopharmacology (Berlin). 161:2002;296-303
22. Diebold K., Michel G., Schweizer J., Diebold-Dorsam M., Fiehn W., Kohl B. Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders? Pharmacopsychiatry. 31:1998;60-67
23. Dirks A., Groenink L., Bouwknecht J.A., Hijzen T.H., Van Der G.J., Ronken E., Verbeek J.S., Veening J.G., Dederen P.J., Korosi A., Schoolderman L.F., Roubos E.W., Olivier B. Overexpression of corticotropin-releasing hormone in transgenic mice and chronic stress-like autonomic and physiological alterations. Eur. J. Neurosci. 16:2002;1751-1760
24. Doniger G.M., Silipo G., Rabinowicz E.F., Snodgrass J.G., Javitt D.C. Impaired sensory processing as a basis for object-recognition deficits in schizophrenia. Am. J. Psychiatry. 158:2001;1818-1826
25. Durany N., Michel T., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., Thome J. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr. Res. 52:2001;79-86
26. Egan M.F., Weinberger D.R. Neurobiology of schizophrenia. Curr. Opin. Neurobiol. 7:1997;701-707
27. Ehrhardt J., Sabel B.A., Schroeder U. Subchronically applied phencyclidine fails to disrupt prepulse inhibition in rats. Eur. Neuropsychopharmacol. 10:1999;69-74
28. Engelberg H. Low serum cholesterol and suicide. Lancet. 339:1992;727-729
29. Fatemi S.H., Earle J.A., McMenomy T. Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Mol. Psychiatry. 5(571):2000;654-663
30. Felder C.C., Bymaster F.P., Ward J., DeLapp N. Therapeutic opportunities for muscarinic receptors in the central nervous system. J. Med. Chem. 43:2000;4333-4353
31. Felder C.C., Porter A.C., Skillman T.L., Zhang L., Bymaster F.P., Nathanson N.M., Hamilton S.E., Gomeza J., Wess J., McKinzie D.L. Elucidating the role of muscarinic receptors in psychosis. Life Sci. 68:2001;2605-2613
32. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., MacGregor R., Alexoff D., Shea C., Schlyer D., Wolf A.P., Warner D., Zezulkova I., Cilento R. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 379:1996;733-736
33. Franken P., Lopez-Molina L., Marcacci L., Schibler U., Tafti M. The transcription factor DBP affects circadian sleep consolidation and rhythmic EEG activity. J. Neurosci. 20:2000;617-625
34. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. U. S. A. 94:1997;587-592
35. Gainetdinov R.R., Mohn A.R., Caron M.G. Genetic animal models: focus on schizophrenia. Trends Neurosci. 24:2001;527-533
36. Gao X.M., Hashimoto T., Tamminga C.A. Phencyclidine (PCP) and dizocilpine (MK801) exert time-dependent effects on the expression of immediate early genes in rat brain. Synapse. 29:1998;14-28
37. Garcia-Roman N., Alvarez A.M., Toro M.J., Montes A., Lorenzo M.J. Lovastatin induces apoptosis of spontaneously immortalized rat brain neuroblasts: involvement of nonsterol isoprenoid biosynthesis inhibition. Mol. Cell. Neurosci. 17:2001;329-341
38. Glantz L.A., Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry. 57:2000;65-73
39. Goldman-Rakic P.S. Regional and cellular fractionation of working memory. Proc. Natl. Acad. Sci. U. S. A. 93:1996;13473-13480
40. Gonzalez-Hernandez J.A., Cedeno I., Pita-Alcorta C., Galan L., Aubert E., Figueredo-Rodriguez P. Induced oscillations and the distributed cortical sources during the Wisconsin card sorting test performance in schizophrenic patients: new clues to neural connectivity. Int. J. Psychophysiol. 48:2003;11-24
41. Goodman A.B. Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 95:1998;7240-7244
42. Gotoh L., Kawanami N., Nakahara T., Hondo H., Motomura K., Ohta E., Kanchiku I., Kuroki T., Hirano M., Uchimura H. Effects of the adenosine A(1) receptor agonist N(6)-cyclopentyladenosine on phencyclidine-induced behavior and expression of the immediate-early genes in the discrete brain regions of rats. Brain Res. Mol. Brain Res. 100:2002;1-12
43. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 41:1991;1-24
44. Greenberg B.D., Segal D.S. Acute and chronic behavioral interactions between phencyclidine (PCP) and amphetamine: evidence for a dopaminergic role in some PCP-induced behaviors. Pharmacol., Biochem. Behav. 23:1985;99-105
45. Guidotti A., Auta J., Davis J.M., Giorgi-Gerevini V., Dwivedi Y., Grayson D.R., Impagnatiello F., Pandey G., Pesold C., Sharma R., Uzunov D., Costa E., DiGiorgi G.V. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch. Gen. Psychiatry. 57:2000;1061-1069
46. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., Haroutunian V., Fienberg A.A. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 98:2001;4746-4751
47. Hazlett E.A., Buchsbaum M.S., Jeu L.A., Nenadic I., Fleischman M.B., Shihabuddin L., Haznedar M.M., Harvey P.D. Hypofrontality in unmedicated schizophrenia patients studied with PET during performance of a serial verbal learning task. Schizophr. Res. 43:2000;33-46
48. Heckers S., Stone D., Walsh J., Shick J., Koul P., Benes F.M. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch. Gen. Psychiatry. 59:2002;521-529
49. Hillbrand M., Waite B.M., Miller D.S., Spitz R.T., Lingswiler V.M. Serum cholesterol concentrations and mood states in violent psychiatric patients: an experience sampling study. J. Behav. Med. 23:2000;519-529
50. Hof P.R., Haroutunian V., Copland C., Davis K.L., Buxbaum J.D. Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. Neurochem. Res. 27:2002;1193-1200
51. Hondo H., Yonezawa Y., Nakahara T., Nakamura K., Hirano M., Uchimura H., Tashiro N. Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. Brain Res. 633:1994;337-342
52. Horita A. An update on the CNS actions of TRH and its analogs. Life Sci. 62:1998;1443-1448
53. Huntsman M.M., Tran B.V., Potkin S.G., Bunney W.E. Jr., Jones E.G. Altered ratios of alternatively spliced long and short gamma2 subunit mRNAs of the gamma-amino butyrate type A receptor in prefrontal cortex of schizophrenics. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15066-15071
54. Hyman S.E., Nestler E.J. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am. J. Psychiatry. 153:1996;151-162
55. Impagnatiello F., Guidotti A.R., Pesold C., Dwivedi Y., Caruncho H., Pisu M.G., Uzunov D.P., Smalheiser N.R., Davis J.M., Pandey G.N., Pappas G.D., Tueting P., Sharma R.P., Costa E. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15718-15723
56. Ito C. Analysis of overall gene expression induced by amphetamine and phencyclidine: novel targets for the treatment of drug psychosis and schizophrenia. Curr. Pharm. Des. 8:2002;147-153
57. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308
58. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:1999;201-225
59. Jentsch J.D., Redmond D.E. Jr., Elsworth J.D., Taylor J.R., Youngren K.D., Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science. 277:1997;953-955
60. Jentsch J.D., Tran A., Taylor J.R., Roth R.H. Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioral and neurochemical evidence. Psychopharmacology (Berlin). 138:1998;89-95
61. Jin J., Yamamoto T., Watanabe S. The involvement of sigma receptors in the choice reaction performance deficits induced by phencyclidine. Eur. J. Pharmacol. 319:1997;147-152
62. Jones C.K., Shannon H.E. Muscarinic cholinergic modulation of prepulse inhibition of the acoustic startle reflex. J. Pharmacol. Exp. Ther. 294:2000;1017-1023
63. Kaplan J.R., Shively C.A., Fontenot M.B., Morgan T.M., Howell S.M., Manuck S.B., Muldoon M.F., Mann J.J. Demonstration of an association among dietary cholesterol, central serotonergic activity, and social behavior in monkeys. Psychosom. Med. 56:1994;479-484
64. Kapur S., Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors - Implications for models of schizophrenia. Mol. Psychiatry. 7:2002;837-844
65. Kelly J.A. Thyrotropin-releasing hormone: basis and potential for its therapeutic use. Essays Biochem. 30:1995;133-149
66. Keshavan M.S., Stanley J.A., Montrose D.M., Minshew N.J., Pettegrew J.W. Prefrontal membrane phospholipid metabolism of child and adolescent offspring at risk for schizophrenia or schizoaffective disorder: an in vivo (31)P MRS study. Mol. Psychiatry. 8:2003;316-323
67. Keshaven M.S., Reynolds C.F. III, Miewald J., Montrose D. Slow-wave sleep deficits and outcome in schizophrenia and schizoaffective disorder. Acta Psychiatr. Scand. 91:1995;289-292
68. Kim S.H., Price M.T., Olney J.W., Farber N.B. Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and alpha2-adrenergic agonists. Mol. Psychiatry. 4:1999;344-352
69. Kinnunen A., Niemi M., Kinnunen T., Kaksonen M., Nolo R., Rauvala H. Heparan sulphate and HB-GAM (heparin-binding growth-associated molecule) in the development of the thalamocortical pathway of rat brain. Eur. J. Neurosci. 11:1999;491-502
70. Krahn L.E., Pankratz V.S., Oliver L., Boeve B.F., Silber M.H. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep. 25:2002;733-736
71. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. 51:1994;199-214
72. Krystal J.H., Abi-Dargham A., Laruelle M., Moghaddam B. Pharmacologic animal models of psychosis. Charney D.S., Neslter E.J., Bunney B.S. Neurobiology of Mental Illness. 1999;214-224 Oxford Univ. Press, New York
73. Lahti A.C., Weiler M.A., Tamara Michaelidis B.A., Parwani A., Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 25:2001;455-467
74. Leonard S., Adams C., Breese C.R., Adler L.E., Bickford P., Byerley W., Coon H., Griffith J.M., Miller C., Myles-Worsley M., Nagamoto H.T., Rollins Y., Stevens K.E., Waldo M., Freedman R. Nicotinic receptor function in schizophrenia. Schizophr. Bull. 22:1996;431-445
75. Lexow N., Joyce J.N., Kim S.J., Phillips J., Casanova M.F., Bird E.D., Kleinman J.E., Winokur A. Alterations in TRH receptors in temporal lobe of schizophrenics: a quantitative autoradiographic study. Synapse. 18:1994;315-327
76. Lieberman J.A., Mailman R.B., Duncan G., Sikich L., Chakos M., Nichols D.E., Kraus J.E. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol. Psychiatry. 44:1998;1099-1117
77. Lin P.T., Gleeson J.G., Corbo J.C., Flanagan L., Walsh C.A. DCAMKL1 encodes a protein kinase with homology to doublecortin that regulates microtubule polymerization. J. Neurosci. 20:2000;9152-9161
78. Lindsay E.A., Baldini A. A mouse gene (Dgcr6) related to the Drosophila gonadal gene is expressed in early embryogenesis and is the homolog of a human gene deleted in DiGeorge syndrome. Cytogenet. Cell Genet. 79:1997;243-247
79. Lipska B.K., Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology. 23:2000;223-239
80. Liu Q., Dwyer N.D., O'Leary D.D. Differential expression of COUP-TFI, CHL1, and two novel genes in developing neocortex identified by differential display PCR. J. Neurosci. 20:2000;7682-7690
81. Liu H., Heath S.C., Sobin C., Roos J.L., Galke B.L., Blundell M.L., Lenane M., Robertson B., Wijsman E.M., Rapoport J.L., Gogos J.A., Karayiorgou M. Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 99:2002;3717-3722
82. Lotto R.B., Asavaritikrai P., Vali L., Price D.J. Target-derived neurotrophic factors regulate the death of developing forebrain neurons after a change in their trophic requirements. J. Neurosci. 21:2001;3904-3910
83. Mahadik S.P., Evans D.R. Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatr. Clin. North Am. 26:2003;85-102
84. Marcotte E.R., Pearson D.M., Srivastava L.K. Animal models of schizophrenia: a critical review. J. Psychiatry Neurosci. 26:2001;395-410
85. Martin P., Carlsson M.L., Hjorth S. Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats. NeuroReport. 9:1998;2985-2988
86. McCarley R.W., Wible C.G., Frumin M., Hirayasu Y., Levitt J.J., Fischer I.A., Shenton M.E. MRI anatomy of schizophrenia. Biol. Psychiatry. 45:1999;1099-1119
87. McGuffin P., Asherson P., Owen M., Farmer A. The strength of the genetic effect. Is there room for an environmental influence in the aetiology of schizophrenia? Br. J. Psychiatry. 164:1994;593-599
88. Meyer G., Perez-Garcia C.G., Gleeson J.G. Selective expression of doublecortin and LIS1 in developing human cortex suggests unique modes of neuronal movement. Cereb. Cortex. 12:2002;1225-1236
89. Michikawa M., Yanagisawa K. Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death. J. Neurochem. 72:1999;2278-2285
90. Middleton F.A., Mirnics K., Pierri J.N., Lewis D.A., Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J. Neurosci. 22:2002;2718-2729
91. Miller E.K. The prefrontal cortex and cognitive control. Nat. Rev., Neurosci. 1:2000;59-65
92. Mirnics K., Middleton F.A., Marquez A., Lewis D.A., Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron. 28:2000;53-67
93. Mirnics K., Middleton F.A., Stanwood G.D., Lewis D.A., Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol. Psychiatry. 6:2001;293-301
94. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 281:1998;1349-1352
95. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17:1997;2921-2927
96. Morgan J.I., Curran T. Proto-oncogene transcription factors and epilepsy. Trends Pharmacol. Sci. 12:1991;343-349
97. Morimoto K., Miyatake R., Nakamura M., Watanabe T., Hirao T., Suwaki H. Delusional disorder: molecular genetic evidence for dopamine psychosis. Neuropsychopharmacology. 26:2002;794-801
98. Murphy K.C., Jones L.A., Owen M.J. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch. Gen. Psychiatry. 56:1999;940-945
99. Nacher J., Crespo C., McEwen B.S. Doublecortin expression in the adult rat telencephalon. Eur. J. Neurosci. 14:2001;629-644
100. Nakki R., Sharp F.R., Sagar S.M., Honkaniemi J. Effects of phencyclidine on immediate early gene expression in the brain. J. Neurosci. Res. 45:1996;13-27
101. Nawa H., Futamura T., Mizuno M., Takahashi M., Toyooka K., Someya T. Contribution of neurotrophic factors and cytokines to schizophrenia. Nippon Rinsho. 61:2003;521-528
102. Nestler E.J. Schizophrenia. An emerging pathophysiology. Nature. 385:1997;578-579
103. Nillni E.A., Sevarino K.A. The biology of pro-thyrotropin-releasing hormone-derived peptides. Endocr. Rev. 20:1999;599-648
104. Nishino S., Ripley B., Mignot E., Benson K.L., Zarcone V.P. CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res. 110:2002;1-7
105. Novak U., Kaye A.H. Extracellular matrix and the brain: components and function. J. Clin. Neurosci. 7:2000;280-290
106. Ogawa S., Okuyama S., Araki H., Nakazato A., Otomo S. A rat model of phencyclidine psychosis. Life Sci. 55:1994;1605-1610
107. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007
108. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., Sesma M.A. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 254:1991;1515-1518
109. Othman S.S., Abdul K.K., Hassan J., Hong G.K., Singh B.B., Raman N. High prevalence of thyroid function test abnormalities in chronic schizophrenia. Aust. N. Z. J. Psychiatry. 28:1994;620-624
110. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. fourth edition:1998;Academic Press, San Diego
111. Pierri J.N., Volk C.L., Auh S., Sampson A., Lewis D.A. Decreased somal size of deep layer 3 pyramidal neurons in the prefrontal cortex of subjects with schizophrenia. Arch. Gen. Psychiatry. 58:2001;466-473
112. Pontecorvo M.J., Clissold D.B., White M.F., Ferkany J.W. N-methyl-D-aspartate antagonists and working memory performance: comparison with the effects of scopolamine, propranolol, diazepam, and phenylisopropyladenosine. Behav. Neurosci. 105:1991;521-535
113. Pulver A.E., Nestadt G., Goldberg R., Shprintzen R.J., Lamacz M., Wolyniec P.S., Morrow B., Karayiorgou M., Antonarakis S.E., Housman D. Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. J. Nerv. Ment. Dis. 182:1994;476-478
114. Ragland J.D., Gur R.C., Raz J., Schroeder L., Kohler C.G., Smith R.J., Alavi A., Gur R.E. Effect of schizophrenia on frontotemporal activity during word encoding and recognition: a PET cerebral blood flow study. Am. J. Psychiatry. 158:2001;1114-1125
115. Rascol O., Payoux P., Ory F., Ferreira J.J., Brefel-Courbon C., Montastruc J.L. Limitations of current Parkinson's disease therapy. Ann. Neurol. 53(Suppl. 3):2003;S3-S12
116. Reiner A., Yekutieli D., Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics. 19:2003;368-375
117. Reynolds G.P., Czudek C., Andrews H.B. Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia. Biol. Psychiatry. 27:1990;1038-1044
118. Reynolds G.P., Beasley C.L., Zhang Z.J. Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons. J. Neural Transm. 109:2002;881-889
119. Riley B., Williamson R. Sane genetics for schizophrenia. Nat. Med. 6:2000;253-255
120. Ripperger J.A., Shearman L.P., Reppert S.M., Schibler U. CLOCK, an essential pacemaker component, controls expression of the circadian transcription factor DBP. Genes Dev. 14:2000;679-689
121. Salin-Pascual R.J., Herrera-Estrella M., Galicia-Polo L., Laurrabaquio M.R. Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol. Psychiatry. 46:1999;141-143
122. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav. Pharmacol. 7:1996;3-23
123. Sawa A., Snyder S.H. Schizophrenia: diverse approaches to a complex disease. Science. 296:2002;692-695
124. Sawaguchi T., Goldman-Rakic P.S. The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J. Neurophysiol. 71:1994;515-528
125. Schmauss C., Haroutunian V., Davis K.L., Davidson M. Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 90:1993;8942-8946
126. Seeman P., Guan H.C., Van Tol H.H. Dopamine D4 receptors elevated in schizophrenia. Nature. 365:1993;441-445
127. Selemon L.D., Goldman-Rakic P.S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry. 45:1999;17-25
128. Sharp F.R., Butman M., Aardalen K., Nickolenko J., Nakki R., Massa S.M., Swanson R.A., Sagar S.M. Neuronal injury produced by NMDA antagonists can be detected using heat shock proteins and can be blocked with antipsychotics. Psychopharmacol. Bull. 30:1994;555-560
129. Sherman A.D., Hegwood T.S., Baruah S., Waziri R. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics. Biol. Psychiatry. 30:1991;1191-1198
130. Shi W.X., Zhang X.X. Dendritic glutamate-induced bursting in the prefrontal cortex: further characterization and effects of phencyclidine. J. Pharmacol. Exp. Ther. 305:2003;680-687
131. Shioiri T., Hamakawa H., Kato T., Fujii K., Murashita J., Inubushi T., Someya T. Frontal lobe membrane phospholipid metabolism and ventricle to brain ratio in schizophrenia: preliminary 31P-MRS and CT studies. Eur. Arch. Psychiatry Clin. Neurosci. 250:2000;169-174
132. Simpson M.D., Slater P., Deakin J.F., Royston M.C., Skan W.J. Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci. Lett. 107:1989;211-215
133. Sobeih M.M., Corfas G. Extracellular factors that regulate neuronal migration in the central nervous system. Int. J. Dev. Neurosci. 20:2002;349-357
134. Squires R.F., Lajtha A., Saederup E., Palkovits M. Reduced [3H]flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains: is selective loss of glutamatergic neurons associated with major psychoses? Neurochem. Res. 18:1993;219-223
135. Stanhope K.J., Mirza N.R., Bickerdike M.J., Bright J.L., Harrington N.R., Hesselink M.B., Kennett G.A., Lightowler S., Sheardown M.J., Syed R., Upton R.L., Wadsworth G., Weiss S.M., Wyatt A. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J. Pharmacol. Exp. Ther. 299:2001;782-792
136. Takahashi S., Horikomi K., Kato T. MS-377, a novel selective sigma(1) receptor ligand, reverses phencyclidine-induced release of dopamine and serotonin in rat brain. Eur. J. Pharmacol. 427:2001;211-219
137. Tsai G., Passani L.A., Slusher B.S., Carter R., Baer L., Kleinman J.E., Coyle J.T. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry. 52:1995;829-836
138. Tsuang D.W., Skol A.D., Faraone S.V., Bingham S., Young K.A., Prabhudesai S., Haverstock S.L., Mena F., Menon A.S., Bisset D., Pepple J., Sauter F., Baldwin C., Weiss D., Collins J., Boehnke M., Schellenberg G.D., Tsuang M.T. Examination of genetic linkage of chromosome 15 to schizophrenia in a large Veterans Affairs Cooperative Study sample. Am. J. Med. Genet. 105:2001;662-668
139. Usiskin S.I., Nicolson R., Krasnewich D.M., Yan W., Lename M., Wudarsky M., Hamburger S.D., Rapoport J.L. Velocardiofacial syndrome in childhood-onset schizophrenia. J. Am. Acad. Child Adolesc. Psych. 38:1999;1536-1543
140. van Kammen D.P., van Kammen W.B., Peters J., Goetz K., Neylan T. Decreased slow-wave sleep and enlarged lateral ventricles in schizophrenia. Neuropsychopharmacology. 1:1988;265-271
141. Vawter M.P., Crook J.M., Hyde T.M., Kleinman J.E., Weinberger D.R., Becker K.G., Freed W.J. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr. Res. 58:2002;11-20
142. Verma A., Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 16:1996;373-379
143. Volk D., Austin M., Pierri J., Sampson A., Lewis D. GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am. J. Psychiatry. 158:2001;256-265
144. Wodicka L., Dong H., Mittmann M., Ho M.H., Lockhart D.J. Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat. Biotechnol. 15:1997;1359-1367
145. Wolkin A., Sanfilipo M., Wolf A.P., Angrist B., Brodie J.D., Rotrosen J. Negative symptoms and hypofrontality in chronic schizophrenia. Arch. Gen. Psychiatry. 49:1992;959-965
146. Wyatt R.J., Murphy D.L., Belmaker R., Cohen S., Donnelly C.H., Pollin W. Reduced monoamine oxidase activity in platelets: a possible genetic marker for vulnerability to schizophrenia. Science. 179:1973;916-918
147. Yan L., Miyake S., Okamura H. Distribution and circadian expression of dbp in SCN and extra-SCN areas in the mouse brain. J. Neurosci. Res. 59:2000;291-295
148. Yeomans J.S. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology. 12:1995;3-16
149. Yotsutsuji T., Saitoh O., Suzuki M., Hagino H., Mori K., Takahashi T., Kurokawa K., Matsui M., Seto H., Kurachi M. Quantification of lateral ventricular subdivisions in schizophrenia by high-resolution three-dimensional magnetic resonance imaging. Psychiatry Res. 122:2003;1-12
150. Zhou C., Qiu Y., Pereira F.A., Crair M.C., Tsai S.Y., Tsai M.J. The nuclear orphan receptor COUP-TFI is required for differentiation of subplate neurons and guidance of thalamocortical axons. Neuron. 24:1999;847-859